Market Cap 405.28B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.18
Forward PE 15.85
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 3,336,800
Avg Vol 5,515,752
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 72%
Beta 0.36
Analysts Strong Sell
Price Target $245.81

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
StocktwitsNews
StocktwitsNews Jan. 5 at 8:40 AM
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment $GHRS $ABBV $ATAI https://stocktwits.com/news/equity/markets/gh-research-stock-grabs-retail-spotlight-ahead-of-fda-update-on-depression-treatment/cmxMLXXR4bQ
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 5 at 8:05 AM
$LLY trading at $1080 with volume 38% below average, while $ABBV at $229 with volume 47% below average. Both in the Healthcare sector - which pharma giant will see a prescription for growth first?
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 5 at 3:01 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 30 2026 Buy in Price: $5.81 - $6.05 Sell Price: $8.60 Profit : +48% (Turn every $1 into $1.48) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Siccest1
Siccest1 Jan. 4 at 11:27 PM
$ABBV $300+ in 2 years.
0 · Reply
_rand0m
_rand0m Jan. 4 at 3:04 PM
0 · Reply
_rand0m
_rand0m Jan. 4 at 2:48 PM
$GALT Who will be taking her to the dance? 1) Eli Lilly 2) AbbVie 3) Novo Nordisk Strong signals for all three. Do your homework. $LLY $ABBV $NVO
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 3 at 9:54 PM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 23 2026 Buy in Price: $4.25 - $4.65 Sell Price: $6.71 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/pricing
0 · Reply
foghornL
foghornL Jan. 3 at 3:54 AM
0 · Reply
GoodTidings
GoodTidings Jan. 2 at 5:55 PM
$SLS $ABBV $MRK $PFE just show your cards so Stergiou can determine who is really seriously engaged to share this great succes and paradigm shift in cancer treatment!!! 😎😎😎
1 · Reply
JFais
JFais Jan. 2 at 2:26 PM
$ABBV $IRWD Interestingly enough, Linzess is a pretty important drug within the Parkinson's community (will be thankful when it goes generic 2029 to 2030, otherwise is something like $500 out of pocket at least for us) Up to 80% of patients with Parkinson's disease experience constipation at some point (slowing GI motility makes difficult for food to move through the digestive tract) Might not sound like a big deal until you experience first-hand as patient or caregiver (can lead to loss of appetite, losing lots of weight and then quality of life falls off pretty quick followed by other more serious complications) Of all the options out there like Miralax (some patients won't want to drink 1-2 glasses daily of powder mixed in), Linzess offers the ease of 1 pill/day (starts working within a few days to a week) Sometimes we forget how important convenience is (makes caregiver's life that much easier)
0 · Reply
Latest News on ABBV
AbbVie: Rocky Near-Term, Positive Long-Term

Jan 4, 2026, 9:04 AM EST - 19 hours ago

AbbVie: Rocky Near-Term, Positive Long-Term


Best Dividend Aristocrats For January 2026

Dec 31, 2025, 8:47 AM EST - 4 days ago

Best Dividend Aristocrats For January 2026

ABT ADM ADP AFL ALB AMCR AOS


Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 7 days ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH


Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 16 days ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO


AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 25 days ago

AbbVie: Unique Mix Of Growth And Value


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 5 weeks ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS


AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 7 weeks ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 7 weeks ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 2 months ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 2 months ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX


AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 2 months ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript


AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 2 months ago

AbbVie: Why Q3 Confirms Its Immunology Dominance


AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 2 months ago

AbbVie Lifts Profit Outlook as Sales Rise


AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 2 months ago

AbbVie Reports Third-Quarter 2025 Financial Results


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 2 months ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH


AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 2 months ago

AbbVie: Deep Discount Before Earnings


StocktwitsNews
StocktwitsNews Jan. 5 at 8:40 AM
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment $GHRS $ABBV $ATAI https://stocktwits.com/news/equity/markets/gh-research-stock-grabs-retail-spotlight-ahead-of-fda-update-on-depression-treatment/cmxMLXXR4bQ
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 5 at 8:05 AM
$LLY trading at $1080 with volume 38% below average, while $ABBV at $229 with volume 47% below average. Both in the Healthcare sector - which pharma giant will see a prescription for growth first?
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 5 at 3:01 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 30 2026 Buy in Price: $5.81 - $6.05 Sell Price: $8.60 Profit : +48% (Turn every $1 into $1.48) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Siccest1
Siccest1 Jan. 4 at 11:27 PM
$ABBV $300+ in 2 years.
0 · Reply
_rand0m
_rand0m Jan. 4 at 3:04 PM
0 · Reply
_rand0m
_rand0m Jan. 4 at 2:48 PM
$GALT Who will be taking her to the dance? 1) Eli Lilly 2) AbbVie 3) Novo Nordisk Strong signals for all three. Do your homework. $LLY $ABBV $NVO
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 3 at 9:54 PM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 23 2026 Buy in Price: $4.25 - $4.65 Sell Price: $6.71 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/pricing
0 · Reply
foghornL
foghornL Jan. 3 at 3:54 AM
0 · Reply
GoodTidings
GoodTidings Jan. 2 at 5:55 PM
$SLS $ABBV $MRK $PFE just show your cards so Stergiou can determine who is really seriously engaged to share this great succes and paradigm shift in cancer treatment!!! 😎😎😎
1 · Reply
JFais
JFais Jan. 2 at 2:26 PM
$ABBV $IRWD Interestingly enough, Linzess is a pretty important drug within the Parkinson's community (will be thankful when it goes generic 2029 to 2030, otherwise is something like $500 out of pocket at least for us) Up to 80% of patients with Parkinson's disease experience constipation at some point (slowing GI motility makes difficult for food to move through the digestive tract) Might not sound like a big deal until you experience first-hand as patient or caregiver (can lead to loss of appetite, losing lots of weight and then quality of life falls off pretty quick followed by other more serious complications) Of all the options out there like Miralax (some patients won't want to drink 1-2 glasses daily of powder mixed in), Linzess offers the ease of 1 pill/day (starts working within a few days to a week) Sometimes we forget how important convenience is (makes caregiver's life that much easier)
0 · Reply
HerbertSowell1052
HerbertSowell1052 Jan. 2 at 1:57 PM
$ABBV defensive name with steady demand Nice balance if market chops
0 · Reply
ZacksResearch
ZacksResearch Jan. 2 at 11:45 AM
$ABBV's neuroscience segment is a game-changer — here's why it's pivotal for growth! 🚀 AbbVie expects a 19% rise in neuroscience sales for 2025, driven by strong performers like Botox Therapeutic and Vraylar, plus notable contributions from Vyalev. With pipeline expansion and recent acquisitions, the company is set to bolster its position further. Discover the full growth strategy here 👉 https://www.zacks.com/stock/news/2811202/heres-how-abbvies-neuroscience-portfolio-is-aiding-top-line-growth?cid=sm-stocktwits-2-2811202-body-27078&ADID=SYND_STOCKTWITS_TWEET_2_2811202_BODY_27078
0 · Reply
N0Bounds
N0Bounds Jan. 2 at 9:26 AM
0 · Reply
TalkMarkets
TalkMarkets Jan. 1 at 3:00 PM
Johnson & Johnson Near Year High $JNJ Also $ABBV $BSX $HALO https://talkmarkets.com/content/stocks--equities/johnson--johnson-near-year-high?post=547778&userid=166882
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 1 at 4:03 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 23 2026 Buy in Price: $4.60 - $4.95 Sell Price: $7.54 Profit : +64% (Turn every $1 into $1.64) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
N0Bounds
N0Bounds Dec. 31 at 10:15 PM
SNSE is the Next big Retail Squeeze!! $KGC $ABBV $TME $SFM $SG 2
0 · Reply
Longbuy1
Longbuy1 Dec. 31 at 9:45 PM
$SLS $PFE $MRK $ABBV ABBV MRK PFE one of your companies is going to buy SLS for 10bil, shares will just converted. Float is 217M with all warrants exercised. Go buy some discounted shares. $GME you can meme SLS now market cap is about 500M. Easy 20-30 bagger that's the floor.
0 · Reply
Longbuy1
Longbuy1 Dec. 31 at 7:13 PM
$SLS where only 41$ short of target value 45$. Question is when $PFE $ABBV $MRK buys us. $GME meme people can still jump in for a 20x bagger.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 31 at 6:58 PM
$SLS $ABBV bought $IMGN for $10.1B based on this data 16.46Month MOS in Platinum Resistant Ovarian Cancer Gps + Keytruda $MRK achieved a better Phase 2 Result - 18.4 Month MOS ... Gps + Keytruda achieved a better MOS than a drug bought for $10.1B ... so, What is Gps Worth to MERCK, just for this Advanced Ovarian Cancer Setting?
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 31 at 6:29 PM
$SLS $ABBV $IMGN $MRK Dr. Julie Cohen Co-Authored this Gps Keytruda Phase 2 Trial Publication - and said MRK would like to Conduct a Phase 3 Trial for Gps + Key in PROC and that Gps would be even more effective in a Maintenance Setting... The entire MRK team, has been waiting for the GPS P3 Results - just like all of us - and know they will be in a Bidding War once the Results are announced, if not Sooner.
0 · Reply
DennisFrank550
DennisFrank550 Dec. 31 at 4:50 PM
$ASML $ABBV $BAC $COST $AMD Looking forward to more updates
0 · Reply
GoodTidings
GoodTidings Dec. 31 at 3:59 PM
$SLS Take into account a $GME scenario here... Some party is taking uncontrolled short risk here!!! It's unjustifiable and not rational to hold or extend your short position at an obvious and successful end period of a trial with the realistic BO bid wat breaking out between $ABBV , $MRK and $PFE 😎😎😎
0 · Reply